Sample collection devices with blood stabilizing agents

A blood, stable technology, applied in the direction of blood transfusion devices, drug packaging, measuring devices, etc., can solve problems such as interpretation difficulties and detracting properties of anticoagulants

Inactive Publication Date: 2014-12-24
BD
View PDF22 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when EDTA blood is in a test tube, changes in cell morphology begin as early as an hour post-collection, creating interpretation difficulties (Narasimha A et al in Indian Hematology & Transfusion Journal of Research (Indian J. Hematol. Blood Transfus.) 24:43-8 (2008)
[0008] Moreover, EDTA causes platelet activation, which detracts from its anticoagulant properties

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sample collection devices with blood stabilizing agents
  • Sample collection devices with blood stabilizing agents
  • Sample collection devices with blood stabilizing agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0079] Example 1 - Iloprost Inhibits EDTA-Mediated Spontaneous Platelet Degranulation

[0080] Platelet activation results in a robust and rapid release of α-granules, dense granules, and lysosomes, the contents of which serve to promote various autocrine and paracrine signaling events. CD62P (P-selectin) is an adhesion molecule that is transiently expressed on the plasma membrane of platelets after α-granule release and that can bind to P-selectin glycoprotein ligand 1 (PSGL-1 / CD162) expressed by leukocytes. connection to mediate platelet-leukocyte aggregates. Although indistinguishable from CD63 surface expression, dense granule and lysosomal release could be measured. Previous studies have shown that ETDA induces the surface expression of CD62P and CD63.

[0081] The effect of EDTA on platelet activation as judged by CD62P and CD63 surface expression was assessed in the presence or absence of a platelet stabilizer (iloprost). Whole blood was collected into tubes containi...

example 2

[0083] Example 2 - Iloprost inhibits agonist-induced platelet degranulation in EDTA for alpha-granule and for compact / lysosomal release.

[0084] The effect of iloprost on platelet activation was studied in the presence of strong platelet activators, ADP and thrombin receptor activating peptide (TRAP). Platelet stimulation was accomplished by adding 300 μL of blood to microcentrifuge tubes containing 10 μL of saline (0.85%), ADP or TRAP-6 and incubating for approximately 2 minutes at room temperature. The final concentrations of ADP and TRAP-6 were 6.5 μM and 32 μM, respectively. Afterwards, whole blood flow cytometry was performed as described above. Blood collection and flow cytometry were done as described in Example 1.

[0085] The addition of ADP increased CD62P expression from 44.6% to 85.1% in the case of only EDTA (resting sample), while TRAP activation reached 99.4% ( Figure 3A ). The addition of iloprost resulted in a decrease in the expression of CD62P to 15.0%...

example 3

[0086] Example 3 - Iloprost inhibits EDTA-mediated degranulation of a sample dwell for a full 24 hours.

[0087] As shown in FIG. 4A , expression of CD62P was analyzed as described in Example 1 at t=0, 2, 8 and 24 hours of sample incubation. Figure 4B Indicates CD62 at each time point and each condition + Percentage of events, shown as mean ± SD for 10 subjects. The table below represents the median fluorescence intensity for all platelet events for 10 subjects at each time point.

[0088]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed are devices for collecting and stabilizing blood or plasma and which contain an anti-coagulant, an antiplatelet agent, and a solubilization agent, and which may optionally include at least one other blood stabilization agent. Methods of making and using the devices in clinical medicine are also provided.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of the filing date of US Provisional Patent Application No. 61 / 594,152, filed February 2, 2012, the disclosure of which is hereby incorporated by reference. Background technique [0003] Description of related fields [0004] Ethylenediaminetetraacetic acid (EDTA) is a polyacid containing four carboxylic acid groups and two amine groups with lone pairs of electrons that chelate calcium and several other metal ions. Based on EDTA's ability to preserve cells and thus ensure the accuracy of clinical blood tests such as complete blood counts (CBC) and peripheral blood smears, EDTA has long been recommended as an antiviral agent in the field of blood collection and clinical hematology. Coagulant choice. Calcium is essential for a wide range of enzymatic reactions in the coagulation cascade. The removal of calcium from collected blood, which interferes with subsequent blood tests, is crit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61J1/05A61M1/02C12M1/24
CPCA61B5/15003A61B5/150274A61B5/150351A61B5/150389A61B5/150473A61B5/150755A61B5/154G01N33/491B01L3/5021B01L2200/16B01L2300/044A01N1/0226
Inventor 兰德尔.艾伦.霍克贾斯蒂娜.杜道尔尼克基思.A.莫斯科维奇弗兰克.市奈科特
Owner BD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap